Hunter C. Smith - 22 Jun 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Jonathan Alspaugh, by power of attorney
Issuer symbol
SYRE
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
4
Filing time
30 Jun 2023, 16:31:16 UTC
Previous filing
21 Jun 2023
Next filing
16 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Stock Option (right to buy) Award $0 +1,950,000 $0.000000 1,950,000 22 Jun 2023 Common Stock 1,950,000 $0.3000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2 The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.